Northern Mariana Islands

This source pass did not verify a recent CNMI psychedelic bill, advisory council, ballot measure, or implementation workstream. The territory’s law reviewed here still treats psilocin and psilocybin as Schedule I substances, and I found no primary-source evidence of deprioritisation or carve-outs for therapeutic use.[1]CNMI code plus CHCC review set[2]CNMI § 2114[2]CNMI § 2114

That means the practical policy context is one of baseline prohibition and limited visible institutional development. For Blossom’s page, the territory should be described as low-activity and low-visibility in psychedelic policy, with ordinary public mental-health services but no verified territory-specific psychedelic framework.[3]CHCC Mental Health Services[1]CNMI code plus CHCC review set[2]CNMI § 2114

The reviewed sources surfaced public mental-health service provision rather than a distinct psychedelic research ecosystem. This source pass did not verify a CNMI university or hospital site running registered psilocybin, MDMA, ibogaine, or ketamine-for-psychiatry trials in this source pass.[1]CNMI code plus CHCC review set[2]CNMI § 2114[3]CHCC Mental Health Services

Accordingly, the territory should not be presented as a research hub. If a local research signal exists, it was not visible in the primary and near-primary materials reviewed here, and that uncertainty should be preserved rather than filled with inference.[1]CNMI code plus CHCC review set[2]CNMI § 2114[2]CNMI § 2114

There is no verified territory implementation machinery for psychedelic services: no licensing office, advisory board, facilitator framework, service-centre rules, or product-testing regime surfaced in the sources reviewed. The operative implementation machinery remains the criminal law and ordinary health-service delivery system.[1]CNMI code plus CHCC review set[2]CHCC Mental Health Services[3]CNMI § 2114

From a practical access perspective, that means there is nothing comparable to Oregon’s roll-out. Any future movement would likely need overt legislative action or a visible public-health or hospital-led programme, neither of which I verified here.[2]CHCC Mental Health Services[1]CNMI code plus CHCC review set[3]CNMI § 2114

The only clearly verifiable public ecosystem node I found was CHCC’s mental-health service structure. This source pass did not verify a dedicated psychedelic clinic network, a known territory advocacy coalition, or a conference/expo footprint focused on psychedelics in CNMI.[1]CHCC Mental Health Services[2]CNMI code plus CHCC review set[3]CNMI § 2114

For this page, restraint matters: CNMI looks more like a jurisdiction where ordinary behavioural-health capacity exists but the documented psychedelic ecosystem is minimal or opaque.[1]CHCC Mental Health Services[2]CNMI code plus CHCC review set[3]CNMI § 2114

Over the next 12 to 24 months, the most likely near-term scenario is continuity rather than reform. Unless a bill, executive initiative, or hospital-led programme emerges, CNMI is unlikely to become a meaningful access or implementation jurisdiction in Blossom’s taxonomy.[1]CNMI code plus CHCC review set[2]CNMI § 2114[2]CNMI § 2114

What matters most to watch is not consumer activity but institutional visibility: any new CNMI legislation, any CHCC or private-sector announcement on ketamine/esketamine capacity, and any published clinical-trial listing tied to Saipan, Tinian or Rota. Until then, access remains conventional and limited.[2]CNMI § 2114[2]CNMI § 2114[3]CHCC Mental Health Services